Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) FCF Margin: 2022-2025

Historic FCF Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Sep 2025 value amounting to -171.27%.

  • bioAffinity Technologies' FCF Margin fell 9815.00% to -171.27% in Q3 2025 from the same period last year, while for Sep 2025 it was -125.53%, marking a year-over-year decrease of 4793.00%. This contributed to the annual value of -78.44% for FY2024, which is 16087.00% up from last year.
  • Per bioAffinity Technologies' latest filing, its FCF Margin stood at -171.27% for Q3 2025, which was up 18.28% from -209.58% recorded in Q2 2025.
  • In the past 5 years, bioAffinity Technologies' FCF Margin ranged from a high of 32.78% in Q2 2022 and a low of -169,528.23% during Q1 2023.
  • For the 3-year period, bioAffinity Technologies' FCF Margin averaged around -16,164.48%, with its median value being -99.21% (2024).
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by 694,234bps in 2023, then skyrocketed by 16,942,902bps in 2024.
  • bioAffinity Technologies' FCF Margin (Quarterly) stood at -55,440.58% in 2022, then soared by 5,536,816bps to -72.42% in 2023, then tumbled by 355bps to -75.97% in 2024, then slumped by 9,815bps to -171.27% in 2025.
  • Its last three reported values are -171.27% in Q3 2025, -209.58% for Q2 2025, and -91.31% during Q1 2025.